Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways

Metformin Potentiates the Effects of Anlotinib in NSCLC via AMPK/mTOR and ROS-Mediated Signaling Pathways

Anlotinib is a novel multi-targeted tyrosine kinase inhibitor with activity against soft tissue sarcoma, small cell lung cancer, and non-small cell lung cancer (NSCLC). Potentiating the anticancer effect of anlotinib in combination strategies remains a clinical challenge. Metformin is an oral agent...

Full description

Bibliographic Details
Main Authors: Zhongling Zhu, Teng Jiang, Huirong Suo, Shan Xu, Cai Zhang, Guoguang Ying, Zhao Yan
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Pharmacology
Subjects:
non-small cell lung cancer
anlotinib
metformin
AMP-activated protein kinase
reactive oxygen species
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.712181/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.712181/full

Similar Items